METHOD AND COMPOSITION FOR ENHANCEMENT OF MALE ERECTILE FUNCTION
A pharmaceutical composition for enhancing male erectile function comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier. Such compositions optionally further comprise compounds selected from an androgen, particularly, testosterone and dihydrotestosterone, a vasodilator, PDE5 inhibitor and prostaglandin E1.
1 . A pharmaceutical composition for enhancing male erectile function comprising an erectile function—enhancing amount of insulin-like growth factor IGF-1 receptor agonist (SC) in admixture with a pharmaceutically-acceptable diluent or carrier.
2 . A composition as claimed in claim 1 comprising an androgen.
3 . A composition as claimed in claim 2 wherein said androgen is selected from testosterone, dihydrotestosterone and a mixture thereof.
4 . A composition as claimed in any one of claims 1 to 3 comprising a vasodilator.
5 . A composition as claimed in any one of claims 1 to 4 comprising PDE5 inhibitor.
6 . A composition as claimed in claim 4 or claim 5 wherein said vasodilator is selected from papaverine, chlorpromazine, atropine, phentolamine, a prostaglandin or mixtures thereof.
7 . A composition as claimed in claim 6 wherein said prostaglandin is prostaglandin E1.
8 . A method of enhancing male erectile function comprising administering to a male a composition comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatomedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier.
9 . A method as claimed in claim 8 wherein said composition comprises an androgen.
10 . A method as claimed in claim 8 or claim 9 wherein said composition comprises a vasodilator.
11 . A method as claimed in claim 10 wherein said vasodilator is selected from papaverine, chlorpromazine, atropine, phentolamine, a prostaglandin and mixtures thereof.
12 . A method as claimed in any one of claims 9 to 11 comprising PDE5 inhibitor.
13 . A method of enhancing male erectile function comprising (a) administering to a male a composition comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatomedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier and (b) administering a composition comprising an androgen.
14 . A method as claimed in claim 13 wherein said androgen is testosterone or dihydrotestosterone.
15 . A method of enhancing male erectile function comprising (a) administering to a male a composition comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatomedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier and (b) administering an enhancing amount of a composition comprising a vasodilator.
16 . A method as claimed in claim 15 wherein said vasodilator is selected from papaverine, chlorpromazine, atropine, phentolamine, a prostaglandin or mixtures thereof.
17 . A method as claimed in claim 16 wherein said prostoglandin is prostaglandin E1.
18 . A use of a composition comprising an effective amount of insulin-like growth factor selected from the group consisting of IGF-1 (Somatomedin-C) and analogue LR3 1GF1 and a pharmaceutically-acceptable carrier or diluents for enhancing male erectile function.
19 . A use as claimed in claim 18 wherein said composition comprises an androgen.
20 . A use as claimed in claim 19 wherein said androgen is selected from testosterone, dihydrotestosterone and mixtures thereof.
21 . A use as claimed in claim 18 or claim 19 wherein said composition comprises a vasodilator.
22 . A use as claimed in claim 21 wherein said vasodilator is selected from papaverine, chlorpromazine, atropine, phentolamine, a prostaglandin or mixtures thereof.
23 . A use as claimed in any one of claims 18 to 22 wherein said composition comprises PDE 5 inhibitor.
24 . A method of manufacturing a medicament intended for the application of enhancing male erectile function characterized in that insulin-like growth factor (IGF) selected from IGF-1 (Somatomedin-C) and LR3 IGF1 is admixed with a pharmaceutically-acceptable carrier.
25 . A method as claimed in claim 24 further comprising admixing said IGF with an androgen.
26 . A method as claimed in claim 24 or claim 25 wherein said IGF is admixed with a vasodilator.
27 . A method as claimed in claim 26 wherein said vasodilator is selected from papaverine, chlorpromazine, atropine, phentolamine, a prostaglandin or mixtures thereof.
28 . A method as claimed in any one of claims 24 to 27 wherein said IGF is admixed with PDE5 inhibitor.
29 . A method as claimed in any one of claims 8 to 17 wherein said administration comprises subcutaneous injection, high pressure jet device, intracavernous injection, intravenous injection, intramuscular injection, intradermal injection, intra-nasal or topical administration.
30 . A method as claimed in claim 29 wherein said administration is topical administration.